Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 327

1.

Expression pattern and functional relevance of epidermal growth factor receptor and cyclooxygenase-2: novel chemotherapeutic targets in pancreatic endocrine tumors?

Bergmann F, Breinig M, Höpfner M, Rieker RJ, Fischer L, Köhler C, Esposito I, Kleeff J, Herpel E, Ehemann V, Friess H, Schirmacher P, Kern MA.

Am J Gastroenterol. 2009 Jan;104(1):171-81. doi: 10.1038/ajg.2008.33.

PMID:
19098866
2.

Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas.

Papouchado B, Erickson LA, Rohlinger AL, Hobday TJ, Erlichman C, Ames MM, Lloyd RV.

Mod Pathol. 2005 Oct;18(10):1329-35.

3.

Expression and therapeutic relevance of heat-shock protein 90 in pancreatic endocrine tumors.

Mayer P, Harjung A, Breinig M, Fischer L, Ehemann V, Malz M, Scherübl H, Britsch S, Werner J, Kern MA, Bläker H, Schirmacher P, Bergmann F.

Endocr Relat Cancer. 2012 May 3;19(3):217-32. doi: 10.1530/ERC-11-0227. Print 2012 Jun.

4.

Fundamental differences in the neural invasion behavior of pancreatic endocrine tumors: relevance for local recurrence rates?

Bergmann F, Ceyhan GO, Rieker RJ, Esposito I, Fischer L, Herpel E, Friess H, Schirmacher P, Kern MA.

Hum Pathol. 2009 Jan;40(1):50-7. doi: 10.1016/j.humpath.2008.06.021. Epub 2008 Sep 11.

PMID:
18789481
5.

Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors.

Fjällskog ML, Lejonklou MH, Oberg KE, Eriksson BK, Janson ET.

Clin Cancer Res. 2003 Apr;9(4):1469-73.

6.

p27: a potential main inhibitor of cell proliferation in digestive endocrine tumors but not a marker of benign behavior.

Canavese G, Azzoni C, Pizzi S, Corleto VD, Pasquali C, Davoli C, Crafa P, Delle Fave G, Bordi C.

Hum Pathol. 2001 Oct;32(10):1094-101.

PMID:
11679944
7.
8.
9.

Effect of simultaneous inhibition of epidermal growth factor receptor and cyclooxygenase-2 in HER-2/neu-positive breast cancer.

Lanza-Jacoby S, Burd R, Rosato FE Jr, McGuire K, Little J, Nougbilly N, Miller S.

Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6161-9.

10.

Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors.

Shida T, Kishimoto T, Furuya M, Nikaido T, Koda K, Takano S, Kimura F, Shimizu H, Yoshidome H, Ohtsuka M, Tanizawa T, Nakatani Y, Miyazaki M.

Cancer Chemother Pharmacol. 2010 Apr;65(5):889-93. doi: 10.1007/s00280-009-1094-6. Epub 2009 Aug 6.

PMID:
19657638
11.

Inhibition of pancreatic and lung adenocarcinoma cell survival by curcumin is associated with increased apoptosis, down-regulation of COX-2 and EGFR and inhibition of Erk1/2 activity.

Lev-Ari S, Starr A, Vexler A, Karaush V, Loew V, Greif J, Fenig E, Aderka D, Ben-Yosef R.

Anticancer Res. 2006 Nov-Dec;26(6B):4423-30.

12.

Cyclooxygenase-2 (COX-2) and epidermal growth factor receptor (EGFR) expression in human pituitary macroadenomas.

Bloomer CW, Kenyon L, Hammond E, Hyslop T, Andrews DW, Curran WJ, Dicker AP.

Am J Clin Oncol. 2003 Aug;26(4):S75-80.

PMID:
12902861
13.

Cyclooxygenase-2 expression is dependent upon epidermal growth factor receptor expression or activation in androgen independent prostate cancer.

Jia RP, Xu LW, Su Q, Zhao JH, Li WC, Wang F, Xu Z.

Asian J Androl. 2008 Sep;10(5):758-64. doi: 10.1111/j.1745-7262.2008.00423.x.

14.

Claudin expression in rectal well-differentiated endocrine neoplasms (carcinoid tumors).

Ishida M, Kushima R, Okabe H.

Oncol Rep. 2009 Jan;21(1):113-7.

PMID:
19082451
15.

The antimetastatic role of thrombomodulin expression in islet cell-derived tumors and its diagnostic value.

Iino S, Abeyama K, Kawahara K, Yamakuchi M, Hashiguchi T, Matsukita S, Yonezawa S, Taniguchi S, Nakata M, Takao S, Aikou T, Maruyama I.

Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6179-88.

16.

Celecoxib induced tumor cell radiosensitization by inhibiting radiation induced nuclear EGFR transport and DNA-repair: a COX-2 independent mechanism.

Dittmann KH, Mayer C, Ohneseit PA, Raju U, Andratschke NH, Milas L, Rodemann HP.

Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):203-12. Epub 2007 Nov 8.

PMID:
17996386
17.

Potential crosstalk between insulin-like growth factor receptor type 1 and epidermal growth factor receptor in progression and metastasis of pancreatic cancer.

Ueda S, Hatsuse K, Tsuda H, Ogata S, Kawarabayashi N, Takigawa T, Einama T, Morita D, Fukatsu K, Sugiura Y, Matsubara O, Mochizuki H.

Mod Pathol. 2006 Jun;19(6):788-96.

18.

Significance of cellular distribution of ezrin in pancreatic cystic neoplasms and ductal adenocarcinoma.

Yeh TS, Tseng JH, Liu NJ, Chen TC, Jan YY, Chen MF.

Arch Surg. 2005 Dec;140(12):1184-90.

PMID:
16365240
19.

Celecoxib inhibits meningioma tumor growth in a mouse xenograft model.

Ragel BT, Jensen RL, Gillespie DL, Prescott SM, Couldwell WT.

Cancer. 2007 Feb 1;109(3):588-97.

20.

Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors.

Kokawa A, Kondo H, Gotoda T, Ono H, Saito D, Nakadaira S, Kosuge T, Yoshida S.

Cancer. 2001 Jan 15;91(2):333-8.

PMID:
11180079

Supplemental Content

Support Center